Home
Scholarly Works
EE68 Assessment of the Cost Utility of Palivizumab...
Journal article

EE68 Assessment of the Cost Utility of Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Preterm Infants Born 29-35 Weeks' Gestational Age in the Philippines

Authors

Del Rosario-Famadico S; Carbonell-Estrany X; Paes B; Tarride J-E; Rodgers-Gray B; Keary I; Fullarton J

Journal

Value in Health, Vol. 28, No. 12,

Publisher

Elsevier

Publication Date

December 1, 2025

DOI

10.1016/j.jval.2025.09.452

ISSN

1098-3015

Contact the Experts team